
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4027000/publications.pdf Version: 2024-02-01



ALASDAID M RADD

#	Article	IF	CITATIONS
1	Characterizing Traumatic Brain Injury and Its Association with Losing Stable Housing in a Community-based Sample. Canadian Journal of Psychiatry, 2022, 67, 207-215.	1.9	9
2	Efficacy of longâ€acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and metaâ€analysis. Microbial Biotechnology, 2022, 16, 589-599.	1.7	27
3	Traumatic brain injury in precariously housed persons: Incidence and risks. EClinicalMedicine, 2022, 44, 101277.	7.1	3
4	Pain, opioid use, depressive symptoms, and mortality in adults living in precarious housing or homelessness: a longitudinal prospective study. Pain, 2022, 163, 2213-2223.	4.2	4
5	Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance. Frontiers in Pharmacology, 2022, 13, 765905.	3.5	3
6	Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. PLoS ONE, 2022, 17, e0267808.	2.5	15
7	Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity. Frontiers in Psychiatry, 2022, 13, .	2.6	5
8	Risk factors for hippocampal cavities in a marginally housed population. Hippocampus, 2022, 32, 567-576.	1.9	3
9	Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110084.	4.8	7
10	Dynamic networks of psychotic symptoms in adults living in precarious housing or homelessness. Psychological Medicine, 2021, , 1-11.	4.5	3
11	A new hypertonic saline assay for analgesic screening in mice: effects of animal strain, sex, and diurnal phase. Canadian Journal of Anaesthesia, 2021, 68, 672-682.	1.6	1
12	A Focused Review of the Metabolic Side-Effects of Clozapine. Frontiers in Endocrinology, 2021, 12, 609240.	3.5	32
13	High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis. Journal of Clinical Psychopharmacology, 2021, 41, 186-190.	1.4	6
14	Relationship between clozapine dose and severity of obsessive-compulsive symptoms. Medical Hypotheses, 2021, 148, 110506.	1.5	1
15	Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. Frontiers in Psychiatry, 2021, 12, 638962.	2.6	21
16	Proteomic identification of select protein variants of the SNARE interactome associated with cognitive reserve in a large community sample. Acta Neuropathologica, 2021, 141, 755-770.	7.7	6
17	Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain. Frontiers in Pharmacology, 2021, 12, 633168.	3.5	20
18	Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis. NPJ Schizophrenia, 2021, 7, 29.	3.6	13

#	Article	IF	CITATIONS
19	Component Processes of Decision Making in a Community Sample of Precariously Housed Persons: Associations With Learning and Memory, and Health-Risk Behaviors. Frontiers in Psychology, 2021, 12, 571423.	2.1	0
20	A ganglionic blocker and adrenoceptor ligands modify clozapine-induced insulin resistance. Psychoneuroendocrinology, 2021, 129, 105257.	2.7	3
21	Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics. Pharmacy (Basel, Switzerland), 2021, 9, 123.	1.6	3
22	Characterization of Bodily Pain and Use of Both Prescription and Non-Prescription Opioids in Tenants of Precarious Housing. Substance Use and Misuse, 2021, 56, 1951-1961.	1.4	5
23	Population pharmacokinetics and dosing of long-acting injectable antipsychotics. Journal of Psychiatry and Neuroscience, 2021, 46, E516-E517.	2.4	0
24	Psychometric properties and correlates of the Beck Depression Inventory in a community-based and homeless or precariously housed sample. Journal of Affective Disorders Reports, 2021, 6, 100229.	1.7	2
25	A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PLoS ONE, 2021, 16, e0246211.	2.5	6
26	Recreational Cannabis Use Before and After Legalization in Women With Pelvic Pain. Obstetrics and Gynecology, 2021, 137, 91-99.	2.4	9
27	Prefrontal fatty acid composition in schizophrenia and bipolar disorder: Association with reelin expression. Schizophrenia Research, 2020, 215, 493-498.	2.0	14
28	A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models. Neuropharmacology, 2020, 175, 107717.	4.1	12
29	Traumatic brain injury in homeless and marginally housed individuals: a systematic review and meta-analysis. Lancet Public Health, The, 2020, 5, e19-e32.	10.0	89
30	Decreased medial entorhinal cortical thickness in olanzapine exposed female rats is not ameliorated by exercise. Pharmacology Biochemistry and Behavior, 2020, 188, 172834.	2.9	0
31	Cerebral Small Vessel Disease, Risk Factors, and Cognition in Tenants of Precarious Housing. Stroke, 2020, 51, 3271-3278.	2.0	16
32	<p>Cannabis Extract CT-921 Has a High Efficacy–Adverse Effect Profile in a Neuropathic Pain Model</p> . Drug Design, Development and Therapy, 2020, Volume 14, 3351-3361.	4.3	9
33	Cognitive decline and mortality in a community-based sample of homeless and precariously housed adults: 9-year prospective study. BJPsych Open, 2020, 6, e21.	0.7	22
34	Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines. Frontiers in Psychiatry, 2020, 11, 617428.	2.6	18
35	Traumatic Brain Injury: An Underappreciated Determinant of Health in Individuals Who are Homeless or Precariously Housed. World Neurosurgery, 2020, 137, 474-475.	1.3	1
36	Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. PLoS Medicine, 2020, 17, e1003172.	8.4	32

#	Article	IF	CITATIONS
37	Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases. Psychotherapy and Psychosomatics, 2020, 89, 151-160.	8.8	19
38	Treatment algorithm for the use of psychopharmacological agents in individuals prenatally exposed to alcohol and/or with diagnosis of fetal alcohol spectrum disorder (FASD). Journal of Population Therapeutics and Clinical Pharmacology, 2020, 27, e1-e13.	1.9	16
39	Amygdala Nuclei Volumes Are Selectively Associated With Social Network Size in Homeless and Precariously Housed Persons. Frontiers in Behavioral Neuroscience, 2020, 14, 97.	2.0	6
40	Cognitive Impairment in Marginally Housed Youth: Prevalence and Risk Factors. Frontiers in Public Health, 2019, 7, 270.	2.7	12
41	Social and structural factors associated with substance use within the support network of adults living in precarious housing in a socially marginalized neighborhood of Vancouver, Canada. PLoS ONE, 2019, 14, e0222611.	2.5	14
42	Prevalence and Risk Factors of Brain Infarcts and Associations With Cognitive Performance in Tenants of Marginal Housing. Journal of the American Heart Association, 2019, 8, e011412.	3.7	11
43	Cognitive profiles and associated structural brain networks in a multimorbid sample of marginalized adults. PLoS ONE, 2019, 14, e0218201.	2.5	9
44	A comparison of regional brain volumes and white matter connectivity in subjects with stimulant induced psychosis versus schizophrenia. Psychopharmacology, 2019, 236, 3385-3399.	3.1	10
45	Repeated Testing With the Hypertonic Saline Assay in Mice for Screening of Analgesic Activity. Anesthesia and Analgesia, 2019, 129, 269-275.	2.2	1
46	Diffusion tensor imaging of neurocognitive profiles in a community cohort living in marginal housing. Brain and Behavior, 2019, 9, e01233.	2.2	7
47	Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatment. Journal of Psychiatry and Neuroscience, 2019, 44, 71-72.	2.4	19
48	Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments. BMC Psychiatry, 2019, 19, 335.	2.6	13
49	Volumes of the Hippocampal Formation Differentiate Component Processes of Memory in a Community Sample of Homeless and Marginally Housed Persons. Archives of Clinical Neuropsychology, 2019, 34, 548-562.	0.5	9
50	Reduced SNAP25 Protein Fragmentation Contributes to SNARE Complex Dysregulation in Schizophrenia Postmortem Brain. Neuroscience, 2019, 420, 112-128.	2.3	9
51	The SNAP25 Interactome in Ventromedial Caudate in Schizophrenia Includes the Mitochondrial Protein ARF1. Neuroscience, 2019, 420, 97-111.	2.3	10
52	Association between Serum Lipids and Antipsychotic Response in Schizophrenia. Current Neuropharmacology, 2019, 17, 852-860.	2.9	26
53	The synaptic pathology of cognitive life. Dialogues in Clinical Neuroscience, 2019, 21, 271-279.	3.7	13

#	Article	IF	CITATIONS
55	Title is missing!. , 2019, 14, e0222611.		0
56	Title is missing!. , 2019, 14, e0222611.		0
57	Title is missing!. , 2019, 14, e0222611.		0
58	Frontotemporal dysregulation of the SNARE protein interactome is associated with faster cognitive decline in old age. Neurobiology of Disease, 2018, 114, 31-44.	4.4	27
59	Cognitive deficits in individuals with methamphetamine use disorder: A meta-analysis. Addictive Behaviors, 2018, 80, 154-160.	3.0	219
60	Rapid Change in Fentanyl Prevalence in a Community-Based, High-Risk Sample. JAMA Psychiatry, 2018, 75, 298.	11.0	40
61	Exercise-induced hippocampal neurogenesis: 5-HT3 receptor antagonism by antipsychotics as a potential limiting factor in Schizophrenia. Molecular Psychiatry, 2018, 23, 2252-2253.	7.9	5
62	Effects of physical activity on the symptoms of Tourette syndrome: A systematic review. European Psychiatry, 2018, 48, 13-19.	0.2	18
63	Statin add-on therapy for schizophrenia: Is the effect the same for clozapine?. Psychiatry Research, 2018, 263, 289-290.	3.3	3
64	Maternal exercise increases but concurrent maternal fluoxetine prevents the increase in hippocampal neurogenesis of adult offspring. Psychoneuroendocrinology, 2018, 91, 186-197.	2.7	9
65	An Intraplantar Hypertonic Saline Assay in Mice for Rapid Screening of Analgesics. Anesthesia and Analgesia, 2018, 127, 548-555.	2.2	6
66	Voluntary running influences the efficacy of fluoxetine in a model of postpartum depression. Neuropharmacology, 2018, 128, 106-118.	4.1	43
67	The utility of psychotropic drugs on patients with Fetal Alcohol Spectrum Disorder (FASD): a systematic review. Journal of Theoretical Social Psychology, 2018, 28, 436-445.	1.9	17
68	Clozapine, elevated heart rate and QTc prolongation. Journal of Psychiatry and Neuroscience, 2018, 43, 71-72.	2.4	18
69	Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis. PLoS ONE, 2018, 13, e0199758.	2.5	8
70	A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child and Adolescent Psychiatry and Mental Health, 2018, 12, 37.	2.5	17
71	Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. Frontiers in Neuroscience, 2018, 12, 203.	2.8	47
72	Clinical and functional characteristics of young adults living in single room occupancy housing: preliminary findings from a 10-year longitudinal study. Canadian Journal of Public Health, 2018, 109, 204-214.	2.3	22

#	Article	IF	CITATIONS
73	Reversal of Dopamine Supersensitivity as a Mechanism of Action of Clozapine. Psychotherapy and Psychosomatics, 2018, 87, 306-307.	8.8	11
74	Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. CNS Drugs, 2018, 32, 917-938.	5.9	15
75	Characterization of white matter integrity deficits in cocaineâ€dependent individuals with substanceâ€induced psychosis compared with nonâ€psychotic cocaine users. Addiction Biology, 2017, 22, 873-881.	2.6	12
76	A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology, 2017, 234, 1535-1547.	3.1	23
77	The Hotel Study—Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons. Canadian Journal of Psychiatry, 2017, 62, 482-492.	1.9	38
78	Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia. Journal of Clinical Psychopharmacology, 2017, 37, 273-274.	1.4	9
79	Structural brain markers are differentially associated with neurocognitive profiles in socially marginalized people with multimorbid illness Neuropsychology, 2017, 31, 28-43.	1.3	13
80	Heart-rate response to alpha2-adrenergic receptor antagonism by antipsychotics. Clinical Autonomic Research, 2017, 27, 407-410.	2.5	5
81	Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample. Molecular Neurodegeneration, 2017, 12, 26.	10.8	17
82	Presynaptic proteins complexin-I and complexin-II differentially influence cognitive function in early and late stages of Alzheimer's disease. Acta Neuropathologica, 2017, 133, 395-407.	7.7	30
83	Verbal memory improvement in first-episode psychosis APOE- ε4 carriers: a pleiotropic effect?. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2945-2953.	2.2	6
84	Traumatic Brain Injury in a Community-Based Cohort of Homeless and Vulnerably Housed Individuals. Journal of Neurotrauma, 2017, 34, 3301-3310.	3.4	19
85	Exercise-associated extrapyramidal symptoms during treatment with long-acting injectable antipsychotic medications: A case report. Clinical Schizophrenia and Related Psychoses, 2017, , .	1.4	2
86	Abstract WMP49: White Matter Hyperintensities in a High Risk Population Living in Marginal Housing (HOTEL study). Stroke, 2017, 48, .	2.0	0
87	Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. Current Neuropharmacology, 2016, 15, 174-183.	2.9	63
88	A Tetra-Primer Amplification Refractory System Technique for the Cost-Effective and Novel Genotyping of Eight Single-Nucleotide Polymorphisms of the Catechol-O-Methyltransferase Gene. Genetic Testing and Molecular Biomarkers, 2016, 20, 465-470.	0.7	4
89	Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 659-664.	1.6	8
90	Factors affecting severity of positive and negative symptoms of psychosis in a polysubstance using population with psychostimulant dependence. Psychiatry Research, 2016, 240, 336-342.	3.3	15

#	Article	IF	CITATIONS
91	Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users. Schizophrenia Research, 2016, 176, 158-163.	2.0	10
92	Response to the Letter to the Editor on "Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?― Journal of Clinical Psychopharmacology, 2016, 36, 745-747.	1.4	0
93	Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia. Schizophrenia Research, 2016, 177, 44-51.	2.0	17
94	Elevated clozapine plasma concentration secondary to a urinary tract infection: proposed mechanisms. Journal of Psychiatry and Neuroscience, 2016, 41, E67-E68.	2.4	12
95	Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration. Journal of Psychiatry and Neuroscience, 2016, 41, E56-E57.	2.4	7
96	Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle. Journal of Clinical Psychopharmacology, 2015, 35, 447-449.	1.4	25
97	A case of pseudo-Stauffer's syndrome related to asenapine use. Schizophrenia Research, 2015, 169, 500-501.	2.0	5
98	Development of a cost-efficient novel method for rapid, concurrent genotyping of five common single nucleotide polymorphisms of the brain derived neurotrophic factor (BDNF) gene by tetra-primer amplification refractory mutation system. International Journal of Methods in Psychiatric Research, 2015, 24, 235-244.	2.1	7
99	White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection. BMC Research Notes, 2015, 8, 515.	1.4	26
100	Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Current Neuropharmacology, 2015, 13, 395-406.	2.9	117
101	Cognition and Plasma Ratio of Clozapine to <i>N</i> -desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia. American Journal of Psychiatry, 2015, 172, 1259-1259.	7.2	11
102	Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. BMJ Open, 2015, 5, e008876.	1.9	34
103	Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample. Molecular Neurodegeneration, 2015, 10, 65.	10.8	34
104	The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values. CNS Drugs, 2015, 29, 975-983.	5.9	14
105	Postoperative delirium following transcatheter aortic valve implantation: a historical cohort study. Canadian Journal of Anaesthesia, 2015, 62, 22-30.	1.6	41
106	Effects of haloperidol and clozapine administration on oxidative stress in rat brain, liver and serum. Neuroscience Letters, 2015, 591, 36-40.	2.1	25
107	Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 234-245.	1.3	24
108	Increased SNARE Protein-Protein Interactions in Orbitofrontal and Anterior Cingulate Cortices in Schizophrenia. Biological Psychiatry, 2015, 78, 361-373.	1.3	52

#	Article	IF	CITATIONS
109	Incidence of and Risk Factors for Delirium After Cardiac Surgery at a Quaternary Care Center: A Retrospective Cohort Study. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 1472-1479.	1.3	33
110	Spines, Synapses, and Schizophrenia. Biological Psychiatry, 2015, 78, 741-743.	1.3	11
111	Incidence and risk factors for impaired mobility in older cardiac surgery patients during the early postoperative period. Geriatrics and Gerontology International, 2015, 15, 276-281.	1.5	12
112	Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia. Canadian Journal of Psychiatry, 2015, 60, S19-25.	1.9	11
113	An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine. PLoS ONE, 2014, 9, e107116.	2.5	18
114	Neurocognitive profiles of marginally housed persons with comorbid substance dependence, viral infection, and psychiatric illness. Journal of Clinical and Experimental Neuropsychology, 2014, 36, 1009-1022.	1.3	18
115	Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment. Journal of Psychiatry and Neuroscience, 2014, 39, E32-E33.	2.4	3
116	Improving Metabolic and Cardiovascular Health at an Early Psychosis Intervention Program in Vancouver, Canada. Frontiers in Psychiatry, 2014, 5, 105.	2.6	16
117	Prevalence and Patterns of Antipsychotic Use in Youth at the Time of Admission and Discharge From an Inpatient Psychiatric Facility. Journal of Clinical Psychopharmacology, 2014, 34, 17-22.	1.4	18
118	Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. International Clinical Psychopharmacology, 2014, 29, 125-137.	1.7	41
119	Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 170-176.	4.8	22
120	Clozapine administered once versus twice daily: Does it make a difference?. Medical Hypotheses, 2014, 82, 225-228.	1.5	17
121	Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 673-682.	3.2	21
122	Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats. Vascular Pharmacology, 2014, 62, 143-149.	2.1	11
123	Much of late life cognitive decline is not due to common neurodegenerative pathologies. Annals of Neurology, 2013, 74, 478-489.	5.3	272
124	Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability. Current Psychiatry Reports, 2013, 15, 355.	4.5	44
125	Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. Current Cardiovascular Risk Reports, 2013, 7, 283-287.	2.0	11
126	Methamphetamine-associated psychosis: a new health challenge in Iran. DARU, Journal of Pharmaceutical Sciences, 2013, 21, 30.	2.0	30

#	Article	IF	CITATIONS
127	A retrospective study of antipsychotic drug switching in a pediatric population. BMC Psychiatry, 2013, 13, 248.	2.6	7
128	Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug and Alcohol Dependence, 2013, 129, 167-179.	3.2	336
129	Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats. Neuroscience, 2013, 255, 147-157.	2.3	27
130	Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. Schizophrenia Research, 2013, 150, 252-257.	2.0	67
131	Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and lloperidone: A Comparison with Olanzapine. PLoS ONE, 2013, 8, e53459.	2.5	36
132	The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing. American Journal of Psychiatry, 2013, 170, 1413-1422.	7.2	82
133	Chronic Benign Neutropenia/Agranulocytosis Associated With Non-Clozapine Antipsychotics. American Journal of Psychiatry, 2013, 170, 1213-1214.	7.2	7
134	Predictors of Persistent Psychotic Symptoms in Persons With Methamphetamine Abuse Receiving Psychiatric Treatment. Journal of Nervous and Mental Disease, 2013, 201, 1085-1089.	1.0	52
135	Relationships Among Depression, PTSD, Methamphetamine Abuse, and Psychosis. Journal of Dual Diagnosis, 2013, 9, 115-122.	1.2	11
136	Antipsychotic polypharmacy increases metabolic dysregulation in female rats Experimental and Clinical Psychopharmacology, 2013, 21, 164-171.	1.8	18
137	Personalized Risk Assessment of Drug-Related Harm Is Associated with Health Outcomes. PLoS ONE, 2013, 8, e79754.	2.5	10
138	Adverse events associated with switching antipsychotics. Journal of Psychiatry and Neuroscience, 2012, 37, E1-E2.	2.4	8
139	Antipsychotic Medications: Linking Receptor Antagonism to Neuropsychological Functioning in First Episode Psychosis. Journal of the International Neuropsychological Society, 2012, 18, 717-727.	1.8	16
140	Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review. Current Neuropharmacology, 2012, 10, 181-196.	2.9	34
141	Synaptic protein deficits are associated with dementia irrespective of extreme old age. Neurobiology of Aging, 2012, 33, 1125.e1-1125.e8.	3.1	26
142	Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system. , 2012, 135, 113-122.		125
143	Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of Psychiatry and Neuroscience, 2012, 37, 407-415.	2.4	52
144	Co-occurring psychosis, substance related disorders, and viral infection in a socially disadvantaged population. International Clinical Psychopharmacology, 2011, 26, e101.	1.7	0

#	Article	IF	CITATIONS
145	Excessive Antipsychotic Dosing in a Canadian Outpatient Population. Psychiatric Services, 2011, 62, 682-683.	2.0	4
146	Withdrawal. Neuromethods, 2011, , 431-459.	0.3	0
147	A Comparison of Antipsychotic Drug-Defined Daily Doses Versus Chlorpromazine Equivalent Doses in Patients With or Without Extrapyramidal Motor Symptoms. Journal of Clinical Psychopharmacology, 2010, 30, 741-743.	1.4	11
148	Profiles of individuals seeking psychiatric help for psychotic symptoms linked to methamphetamine abuse – baseline results from the MAPS (methamphetamine and psychosis study). Mental Health and Substance Use: Dual Diagnosis, 2010, 3, 168-181.	0.5	10
149	Prenatal tobacco exposure in first-episode psychosis. Schizophrenia Research, 2010, 119, 271-272.	2.0	5
150	Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study. Schizophrenia Research, 2010, 123, 273-275.	2.0	5
151	Smoking cessation interventions among individuals in methadone maintenance: A brief review. Journal of Substance Abuse Treatment, 2010, 38, 191-199.	2.8	41
152	Effects of sub-chronic clozapine and haloperidol administration on brain lipid levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 669-673.	4.8	11
153	A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 945-954.	4.8	65
154	Preclinical models of antipsychotic drug-induced metabolic side effects. Trends in Pharmacological Sciences, 2010, 31, 484-497.	8.7	97
155	Effect of hypertriglyceridemia on the pharmacokinetics and blood–brain barrier penetration of clozapine and norclozapine following administration to rats. European Neuropsychopharmacology, 2010, 20, 545-552.	0.7	9
156	A Novel Mechanism and Treatment Target for Presynaptic Abnormalities in Specific Striatal Regions in Schizophrenia. Neuropsychopharmacology, 2010, 35, 1226-1238.	5.4	54
157	Medication Errors in Psychiatry. CNS Drugs, 2010, 24, 595-609.	5.9	42
158	Persistent Antipsychotic Polypharmacy and Excessive Dosing in the Community Psychiatric Treatment Setting. Journal of Clinical Psychiatry, 2010, 71, 566-573.	2.2	104
159	Impairment of memory consolidation by galanin correlates with in vivo inhibition of both LTP and CREB phosphorylation. Neurobiology of Learning and Memory, 2009, 92, 429-438.	1.9	23
160	Role of estradiol withdrawal in â€~anhedonic' sucrose consumption: A model of postpartum depression. Physiology and Behavior, 2009, 97, 259-265.	2.1	72
161	Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophrenia Research, 2009, 108, 258-264.	2.0	23
162	Do serum lipids predict response to clozapine treatment?. Journal of Psychiatry and Neuroscience, 2009, 34, 168.	2.4	12

#	Article	IF	CITATIONS
163	A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. Journal of Psychiatry and Neuroscience, 2009, 34, 433-42.	2.4	19
164	Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins. European Journal of Neuroscience, 2008, 27, 2568-2574.	2.6	52
165	Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophrenia Research, 2008, 100, 252-260.	2.0	70
166	Altered performance of reelin-receptor ApoER2 deficient mice on spatial tasks using the Barnes maze Behavioral Neuroscience, 2007, 121, 1101-1105.	1.2	15
167	The reelin receptors VLDLR and ApoER2 regulate sensorimotor gating in mice. Neuropharmacology, 2007, 52, 1114-1123.	4.1	23
168	Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. CNS Drugs, 2007, 21, 699-714.	5.9	28
169	Determination of Clozapine and its Metabolite, Norclozapine in Various Biological Matrices Using High-Performance Liquid Chromatography. Drug Development and Industrial Pharmacy, 2007, 33, 1158-1166.	2.0	15
170	A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia. Schizophrenia Research, 2007, 94, 288-292.	2.0	31
171	Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. Journal of Neurochemistry, 2007, 103, 070611013409001-???.	3.9	38
172	Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. Journal of Psychiatry and Neuroscience, 2007, 32, 331-8.	2.4	66
173	A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neuroscience Letters, 2006, 405, 111-115.	2.1	61
174	lloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology, 2006, 51, 457-465.	4.1	49
175	Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway. International Journal of Neuropsychopharmacology, 2006, 9, 457.	2.1	30
176	Relevance of Presynaptic Proteins to Neuropsychiatric Disorders. , 2006, , 391-408.		3
177	The need for speed: an update on methamphetamine addiction. Journal of Psychiatry and Neuroscience, 2006, 31, 301-13.	2.4	279
178	Hippocampal Complexin Proteins and Cognitive Dysfunction in Schizophrenia. Archives of General Psychiatry, 2005, 62, 263.	12.3	107
179	Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity. Journal of Neurochemistry, 2005, 93, 493-501.	3.9	99
180	Prenatal Ethanol Exposure in Rats Decreases Levels of Complexin Proteins in the Frontal Cortex. Alcoholism: Clinical and Experimental Research, 2005, 29, 1915-1920.	2.4	20

#	Article	IF	CITATIONS
181	Galanin receptors as novel drug targets for the treatment of depression and anxiety. Drug Development Research, 2005, 65, 227-236.	2.9	4
182	Psychostimulant withdrawal as an inducing condition in animal models of depression. Neuroscience and Biobehavioral Reviews, 2005, 29, 675-706.	6.1	98
183	A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proceedings of the United States of America, 2005, 102, 874-879.	7.1	123
184	Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology, 2005, 196, 266-272.	4.1	60
185	The Selective Serotonin-2A Receptor Antagonist M100907 Reverses Behavioral Deficits in Dopamine Transporter Knockout Mice. Neuropsychopharmacology, 2004, 29, 221-228.	5.4	119
186	Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia. European Journal of Neuroscience, 2004, 20, 303-307.	2.6	55
187	Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10470-10475.	7.1	131
188	High frequency of TNF alleles \$minus;238A and \$minus;376A in individuals from northern Sardinia. Cytokine, 2004, 26, 149-154.	3.2	23
189	Tolerance to the anhedonic effects of lipopolysaccharide is associated with changes in syntaxin immunoreactivity in the nucleus accumbens. International Journal of Neuropsychopharmacology, 2003, 6, 23-34.	2.1	23
190	Role of Integrin-Linked Kinase in Nerve Growth Factor-Stimulated Neurite Outgrowth. Journal of Neuroscience, 2003, 23, 1638-1648.	3.6	89
191	High levels of estradiol impair spatial performance in the Morris water maze and increase †depressive-like' behaviors in the female meadow vole. Physiology and Behavior, 2002, 77, 217-225.	2.1	49
192	A â€~crash' course on psychostimulant withdrawal as a model of depression. Trends in Pharmacological Sciences, 2002, 23, 475-482.	8.7	146
193	Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of d-amphetamine. Pharmacology Biochemistry and Behavior, 2002, 71, 293-299.	2.9	52
194	Exposure to Repeated, Intermittent d-amphetamine Induces Sensitization of HPA Axis to a Subsequent Stressor. Neuropsychopharmacology, 2002, 26, 286-294.	5.4	54
195	Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats. Psychopharmacology, 2002, 159, 196-202.	3.1	22
196	Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. Behavioural Brain Research, 2001, 122, 1-9.	2.2	242
197	Paradoxical effects of chronic corticosterone on forced swim behaviours in aged male and female rats. European Journal of Pharmacology, 2001, 424, 203-209.	3.5	59
198	Chronic corticosterone enhances the rewarding effect of hypothalamic self-stimulation in rats. Brain Research, 2000, 875, 196-201.	2.2	40

#	Article	IF	CITATIONS
199	Sex differences in forced-swim and open-field test behaviours after chronic administration of melatonin. European Journal of Pharmacology, 2000, 402, 87-93.	3.5	108
200	Withdrawal following repeated exposure to d -amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement. Psychopharmacology, 1999, 141, 99-106.	3.1	171
201	Effects of Withdrawal from an Escalating Dose Schedule of d-Amphetamine on Sexual Behavior in the Male Rat. Pharmacology Biochemistry and Behavior, 1999, 64, 597-604.	2.9	89
202	Chronic mild stress has no effect on responding by rats for sucrose under a progressive ratio schedule. Physiology and Behavior, 1998, 64, 591-597.	2.1	66
203	Stimulation of the Ventral Subiculum of the Hippocampus Evokes Glutamate Receptor-mediated Changes in Dopamine Efflux in the Rat Nucleus Accumbens. European Journal of Neuroscience, 1997, 9, 902-911.	2.6	187
204	Effects of chronic mild stress on motivation for sucrose: mixed messages. Psychopharmacology, 1997, 134, 361-362.	3.1	26